Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome

Background  Cutaneous T‐cell lymphoma (CTCL) is a slowly progressive malignancy for which there is no cure. Therefore, accurate prediction of prognosis is important for the conduct of clinical trials and for counselling of individuals.

[1]  A. Oseroff,et al.  Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. , 1997, Journal of the American Academy of Dermatology.

[2]  H. Kerl,et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.

[3]  P. Bunn,et al.  Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. , 1979, Cancer treatment reports.

[4]  H. Stein,et al.  High detection rate of T-cell receptor beta chain rearrangements in T-cell lymphoproliferations by family specific polymerase chain reaction in combination with the GeneScan technique and DNA sequencing. , 2000, Blood.

[5]  Jun Yan.  Survival Analysis: Techniques for Censored and Truncated Data , 2004 .

[6]  S. Goerdt,et al.  Extracorporeal photopheresis and interferon-α in advanced cutaneous T-cell lymphoma , 1997, The Lancet.

[7]  A. Varghese,et al.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.

[8]  J. Scarisbrick,et al.  Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. , 2001, Blood.

[9]  R. Edelson,et al.  Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma. , 1994, Archives of dermatology.

[10]  E Graf,et al.  Assessment and comparison of prognostic classification schemes for survival data. , 1999, Statistics in medicine.

[11]  A. Domingo,et al.  Sézary Syndrome and Related Variants of Classic Cutaneous T-cell Lymphoma. A Descriptive and Prognostic Clinicopathologic Study of 29 Cases* , 2003, Leukemia & lymphoma.

[12]  M. Schemper,et al.  Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.

[13]  H. Stein,et al.  Clonal T‐cell receptor γ‐chain gene rearrangement by PCR‐based GeneScan analysis in advanced cutaneous T‐cell lymphoma: a critical evaluation , 1999, The Journal of pathology.

[14]  E. Sausville.  T-cell leukemia-lymphoma and mycosis fungoides. , 1992, Current opinion in oncology.

[15]  H. Kerl,et al.  Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. , 2002, Blood.

[16]  M. Weinstock,et al.  Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. , 1988, JAMA.

[17]  H. Stein,et al.  Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement , 1997, The Lancet.

[18]  E. Sausville,et al.  Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. , 1985, Human pathology.

[19]  Malcolm S. Ke,et al.  Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). , 2002, Archives of dermatology.

[20]  R. Kurzrock,et al.  Prognostic factor analysis in mycosis fungoides/Sézary syndrome. , 1999, Journal of the American Academy of Dermatology.

[21]  R. Dummer,et al.  Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept. , 1999, Archives of dermatology.

[22]  H. Stein,et al.  T-cell clonality of undetermined significance. , 2001, Blood.

[23]  C. Klemke,et al.  Clonal T cell receptor γ‐chain gene rearrangement by PCR‐based GeneScan analysis in the skin and blood of patients with parapsoriasis and early‐stage mycosis fungoides , 2002, The Journal of pathology.

[24]  A. Varghese,et al.  Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. , 1996, Archives of dermatology.

[25]  D. Ramsay,et al.  Relative frequency of various forms of primary cutaneous lymphomas. , 2000, Journal of the American Academy of Dermatology.

[26]  G. Burg,et al.  Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. , 2002, Journal of the American Academy of Dermatology.

[27]  A. Varghese,et al.  Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. , 1999, Archives of dermatology.

[28]  B. Dréno,et al.  Prognostic factors in Sézary syndrome: a study of 28 patients , 2003, The British journal of dermatology.

[29]  A. Varghese,et al.  Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. , 1995, Archives of dermatology.